肿瘤坏死因子受体超家族成员7(TNFRSF7)活性蛋白
Active Tumor Necrosis Factor Receptor Superfamily, Member 7 (TNFRSF7)
CD27; S152; T14; Tp55; CD27L receptor;
- 编号UAPB043Hu01
- 物种Homo sapiens (Human，人) 相同的名称，不同的物种。
- 缓冲液成份20mM Tris, 150mM NaCl缓冲液（pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300）
- 性状冻干粉
- 纯度> 95%
- 等电点7.2
- 应用Cell culture; Activity Assays.
- 下载 英文说明书 中文说明书
- 规格 10µg50µg 200µg 1mg 5mg
- 价格 ¥ 540 ¥ 1350 ¥ 2700 ¥ 8100 ¥ 20250
- 欲了解实际交易价格和更多情况，请与当地经销商联系!
-
产品包装(模拟)
-
产品包装(模拟)
-
SDS-PAGE图
-
Figure. Western Blot; Sample: Recombinant TNFRSF7, Human.
-
通过ISO 9001、ISO 13485质量体系认证
活性实验
TNFRSF7 (Tumor necrosis factor receptor superfamily member 7), also known as CD27 antigen, is a member of the TNF-receptor superfamily. This receptor is thought to be involved in tumor necrosis factor-activated receptor activity by binding with TNFs. Thus, a binding ELISA assay was conducted to detect the association of TNFRSF7 with TNFa. Briefly, recombinant human TNFRSF7 were diluted serially in PBS with 0.01%BSA (pH 7.4). Duplicate samples of 100uL were then transferred to TNFa-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-TNFRSF7 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of TNFRSF7 with TNFa was shown in Figure 1 and this effect was in a dose dependent manner.
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
储存
避免反复冻融。2-8°C不超过一个月，-80°C不超过12个月。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定，具体方法如下：在37°C孵育48小时，没有显著的降解或者沉淀产生。保质期内，在适当的条件下存储，损失率低于5%。
